Pharmacological characterization of vasomotor activity of human musculocutaneous perforator artery and vein.
Vasospasm is one of the main causes of skin ischemic necrosis in cutaneous and musculocutaneous flap surgery, but the pathogenic mechanism is unclear. We planned to test the hypothesis derived from clinical impression that veins are more susceptible to vasospasm than arteries in flap surgery and, once established, that venous vasospasm is difficult to resolve and more detrimental than arterial vasospasm. To this end, we investigated the differences in sensitivity to vasoconstrictors and vasodilators between the human musculocutaneous perforator (MCP) artery and vein by measuring the isometric tension of arterial and venous rings suspended in organ chambers. Vascular contraction was expressed as a percentage of the tension induced by 50 mM KCl. Relaxation was expressed as a percentage of contraction induced by a submaximal concentration (3 x 10(-9) M) of endothelin-1 (ET-1). We observed that the vasoconstrictor potency of norepinephrine was significantly higher in the MCP vein than in the MCP artery. The vasoconstrictor potency of ET-1 and the thromboxane A(2) mimetic U-46619 were similar in the MCP vein and artery, but the maximal contraction induced by ET-1 and U-46619 was significantly higher in the MCP vein than in the MCP artery. On the other hand, the MCP vein was less sensitive than the MCP artery to the relaxation effect of nitroglycerin, nifedipine, and lidocaine. These differences between the human MCP artery and vein in response to vasoactive agents lend support to the clinical impression in flap surgery that veins appear to be more susceptible to vasospasm than arteries and venous vasospasm seems to be more difficult to resolve than arterial vasospasm in cutaneous and musculocutaneous flap surgery.
Zhang
J
J
Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8.
Lipa
J E
JE
Black
C E
CE
Huang
N
N
Neligan
P C
PC
Ling
F T
FT
Levine
R H
RH
Semple
J L
JL
Pang
C Y
CY
D001158:Arteries / Q000187:drug effects / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D018482:Muscle, Skeletal / Q000098:blood supply*; D012867:Skin / Q000098:blood supply*; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology; D014666:Vasomotor System / Q000187:drug effects / Q000502:physiology*; D014680:Veins / Q000187:drug effects / Q000502:physiology
D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents